EP1556007A2 - Composes tetracycline substituee servant au traitement du paludisme - Google Patents

Composes tetracycline substituee servant au traitement du paludisme

Info

Publication number
EP1556007A2
EP1556007A2 EP03781398A EP03781398A EP1556007A2 EP 1556007 A2 EP1556007 A2 EP 1556007A2 EP 03781398 A EP03781398 A EP 03781398A EP 03781398 A EP03781398 A EP 03781398A EP 1556007 A2 EP1556007 A2 EP 1556007A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
substituted
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03781398A
Other languages
German (de)
English (en)
Other versions
EP1556007A4 (fr
Inventor
Michael Draper
Mark L. Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Priority to EP10171327A priority Critical patent/EP2277504A1/fr
Publication of EP1556007A2 publication Critical patent/EP1556007A2/fr
Publication of EP1556007A4 publication Critical patent/EP1556007A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • R 4 is NR 4 R 4 , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 3 , R 11 and R 12 are each hydrogen, or a pro-drug moiety;
  • R 10 is hydrogen, a prodrug moiety, or linked to R 9 to form a ring;
  • R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
  • this invention also pertains to pharmaceutical compositions which include an effective amount of one of the above-described substituted tetracycline compounds and a pharmaceutically acceptable carrier
  • This invention also features a packaged malarial treatment, including one or more of the substituted tetracycline compounds of the invention packaged with instructions for using the compound to treat malaria.
  • this invention pertains to methods of treating or preventing malaria in a subject, by administering an effective amount of a substituted tetracycline compound.
  • tetracycline compounds includes tetracycline family members such as methacycline, sancycline, apicycline, clomocycline, guamecycline, meglucycline, mepylcycline, penimepicycline, pipacycline, etamocycline, penimocycline, etc. as well as other tetracycline compounds having the characteristic naphthacene A-B-C-D ring structure. Additional tetracycline compounds can be found, for example, in U.S. Patent Application Serial No.: 09/234,847, and U.S. Patents Nos.
  • tetracyclines regardless of specific formulation or chemical structure, were found to be highly effective pharmacologically against rickettsiae, a number of gram-positive and gram-negative bacteria, and the agents responsible for lymphogranuloma venereum, including conjunctivitis, and psittacosis.
  • tetracyclines became known as "broad spectrum" antibiotics.
  • the tetracyclines as a class rapidly became widely used for therapeutic purposes.
  • the substituted tetracycline compound of the invention may have anti-microbial gram positive activity, as measured by assays known in the art or the assay described in Example 6.
  • the anti-microbial gram positive activity of the substituted tetracycline compound is greater than about 0.0001 ⁇ g/ml, greater than about 0.05 ⁇ g/ml, greater than about 0.5 ⁇ g/ml, greater than about 1.0 ⁇ g/ml, or greater than about 5.0 ⁇ g/ml. Values and ranges included and/or intermediate of the values set forth herein are also intended to be within the scope of the present invention.
  • the substituted tetracycline compound of the invention has a cytotoxicity which allows the compound to be administered in an effective amount to the subject with out causing prohibitive cytotoxic side effects.
  • the cytotoxicity of the substituted tetracycline compound of the invention is greater than about 10 ⁇ g/ml, about 15 ⁇ g/ml, about 20 ⁇ g/ml, or about 25 ⁇ g/ml as measured by cytoxicity assays known in the art such as the assay described in Example 5.
  • the substituted tetracycline compound of the invention has a MIC which allows it to perform its intended function, e.g., treat or prevent malaria in a subject.
  • the MIC is a measure of the concentration of the compound necessary to inhibit the malaria parasite.
  • the MIC can be tested using methods known in the art as well as the in vitro method described in Example 3 or the in vivo method described in Example 4.
  • the MIC of a substituted tetracycline compound as measured in vivo is about 500 mg/kg or less, about 250 mg/kg or less, about 200 mg/kg or less, about 190 mg/kg or less, about 180 mg/kg or less, about 170 mg/kg or less, about 160 mg/kg or less, about 150 mg/kg or less, about 140 mg/kg or less, about 130 mg/kg or less, about 120 mg/kg or less, about 110 mg/kg or less, about 100 mg/kg or less, about 95 mg/kg or less, about 90 mg/kg or less, about 85 mg/kg or less, about 80 mg/kg or less, about 75 mg/kg or less, about 70 mg/kg or less, about 65 mg/kg or less, about 60 mg/kg or less, about 55 mg/kg or less, about 50 mg/kg or less, about 45 mg/kg or less, about 40 mg/kg or less, about 35 mg/kg or less, about 30 mg/kg or less, about 29 mg/kg or less, about 28 mg
  • This invention provides a method for treating or preventing malaria in a subject by administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented in said subject.
  • X is CHC(R 13 Y'Y), CR 6' R 6 , S, NR 6 , or O;
  • R 2 , R 2 , R 4 , and R 4 are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 4 is NR 4 R 4 , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 3 , R 1 ' and R 12 are each hydrogen, or a pro-drug moiety
  • R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
  • R 6 and R 6 are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • R 7 is hydrogen, alkylamino, dialkylamino, or a malaria interacting moiety;
  • R 9 is hydrogen, or a malaria interacting moiety
  • R is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; with the proviso that the compound of formula I is not oxytetracycline, demeclocycline, doxycycline, chlorotetracycline, minocycline, or tetracycline; and pharmaceutically acceptable salts thereof.
  • Examples of compounds of formula I which can be used in the methods of the invention include substituted tetracycline compounds wherein R , R , R , R , and R 12 are hydrogen; R 4 is NR R" and R 4' and R 4" are alkyl (e.g., methyl); and X is CR 6 R 6' .
  • the substituted tetracycline compounds of the invention may also include substituted minocycline derivatives, e.g., wherein R , R , and R are hydrogen, and R is dialkylamino.
  • the substituted tetracycline compound of the invention is substituted at the 7 or 9 position with a malaria interacting moiety.
  • the term "malaria interacting moiety” is a moiety which allows the substituted tetracycline compound of the invention to perform its intended function, e.g., treat or prevent malaria. It may interact with the malaria parasite or allow other portions of the tetracycline molecule to interact with the parasite. It also may allow the molecule to treat malaria by affecting the way the tetracycline compound interacts with the malaria parasite, the subject, or other microbes.
  • the malaria interacting moiety may alter the tetracycline compounds' properties such that the resulting compound is, for example, non- antibacterial.
  • the malaria interacting moiety is a moiety which comprises from about 2 to 40, from about 3 to 30, from about 3 to 20 carbon, nitrogen, oxygen and sulfur atoms.
  • the malaria interacting moiety may further be substituted with hydrogen and other substituents (e.g., halogens) which are not counted amongst the 2 to 40, from about 3 to 30, from about 3 to 20 atoms.
  • the malaria interacting moiety comprises an aryl or heteroaryl moiety.
  • the aryl or heteroaryl moiety can be substituted with any substituent which allows it to perform its intended function.
  • Examples of malaria interacting moieties include aryl groups such as phenyl and heteroaryl groups (e.g., furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, pyridinyl, pyrazolyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, and deazapurinyl).
  • aryl groups such as phenyl and heteroaryl groups (e.g., furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinoliny
  • the aryl group may be substituted or unsubstituted.
  • substituents include, but are not limited, alkyl, alkenyl, alkynyl, aralkyl, alkoxyalkyl, aminoalkyl, amino, nitro, cyano, halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxy, thiol, formyl, acetyl, acyl, alkoxy (e.g., methylene dioxy, methoxy, ethoxy, propoxy, etc.) and heterocyclic (e.g., morpholino, piperazine, etc.).
  • the substituents may be further substituted as appropriate.
  • R a and R b are each independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, or heterocyclic (R a and R b may optionally be linked to form a ring); g is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; n is O, 1, 2, or 3; and X a , X b , X c , X d , and X e are each independently optionally substituted carbon, oxygen, nitrogen, or sulfur. Furthermore, each carbon atom of the malaria interacting moieties shown above may be further substituted with substituents which allow the tetracycline compound to perform its intended function.
  • substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thio, amid
  • the methods of the invention also include the use of substituted tetracycline compounds which are sancycline derivatives, e.g., wherein R 5 , R 6 , and R 6 are hydrogen.
  • sancycline derivatives include tetracycline compounds wherein R 7 is a malaria interacting moiety.
  • malaria interacting moieties which may be used for substituted sancycline compounds of the invention include those described above.
  • other examples of malaria interacting moieties include, but are not limited to, aryl group such as substituted or unsubstituted phenyl or a heteroaryl moieties.
  • substituted sancycline compounds include compounds wherein R 9 is hydrogen or a malaria interacting moiety.
  • the substituted tetracycline compound has a molecular weight of less than 800, less than 600, less than 550, less than 500, or less than 400 grams/mole.
  • alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 0 for straight chain, C 3 -C 6 for branched chain).
  • cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
  • C 2 -C 6 includes alkenyl groups containing 2 to 6 carbon atoms.
  • alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
  • lower alkyl as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure.
  • Lower alkenyl and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.
  • COS-1 and CHO cell suspensions are prepared, seeded into 96-well tissue culture treated black-walled microtiter plates (density determined by cell line), and incubated overnight at 37°C, in 5% CO 2 and approximately 95% humidity. The following day serial dilutions of drug are prepared under sterile conditions and transferred to cell plates. Cell/Drug plates are incubated under the above conditions for 24 hours. Following the incubation period, media/drug is aspirated and 50 ⁇ l of Resazurin is added. Plates are then incubated under the above conditions for 2 hours and then in the dark at room temperature for an additional 30 minutes. Fluorescence measurements are taken (excitation 535 nm, emission 590 n ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une méthode de traitement ou de prévention du paludisme chez un sujet. Cette méthode consiste à administrer au sujet une quantité efficace d'un composé tétracycline substituée permettant de traiter ou de prévenir le paludisme. Dans une variante, cette invention concerne des compositions pharmaceutiques qui contiennent une quantité efficace d'un composé tétracycline visant à traiter le paludisme chez un sujet ainsi qu'un excipient pharmaceutiquement acceptable. Les composés tétracycline substituée de cette invention peuvent être associés à un ou plusieurs composés antipaludiques et peuvent être utilisés pour traiter ou prévenir un paludisme résistant à un ou plusieurs autres composés antipaludiques.
EP03781398A 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme Withdrawn EP1556007A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10171327A EP2277504A1 (fr) 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42125902P 2002-10-24 2002-10-24
US421259P 2002-10-24
PCT/US2003/033927 WO2004038001A2 (fr) 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme

Publications (2)

Publication Number Publication Date
EP1556007A2 true EP1556007A2 (fr) 2005-07-27
EP1556007A4 EP1556007A4 (fr) 2008-12-17

Family

ID=32176689

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10171327A Withdrawn EP2277504A1 (fr) 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme
EP03781398A Withdrawn EP1556007A4 (fr) 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10171327A Withdrawn EP2277504A1 (fr) 2002-10-24 2003-10-24 Composes tetracycline substituee servant au traitement du paludisme

Country Status (6)

Country Link
EP (2) EP2277504A1 (fr)
JP (2) JP2006503898A (fr)
AU (3) AU2003287218C1 (fr)
CA (1) CA2502464A1 (fr)
IL (1) IL209319A0 (fr)
WO (1) WO2004038001A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250331A1 (en) * 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
CA2492273C (fr) 2002-07-12 2013-02-05 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee en 3, 10, et 12a
EA201001081A1 (ru) 2003-07-09 2011-02-28 Пэрэтек Фамэсьютикэлс, Инк. Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
EP2292590A3 (fr) * 2003-07-09 2012-05-02 Paratek Pharmaceuticals, Inc. Promédicaments de composés de tétracycline 9-aminométhylé
AU2005244988C1 (en) 2004-05-21 2012-06-28 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2284156A3 (fr) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Composés de tétracycline substituée
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
US8486921B2 (en) 2006-04-07 2013-07-16 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP3056487B1 (fr) 2006-10-11 2018-02-21 President and Fellows of Harvard College Synthèse d'un intermédiaire de l'énone
EP2452935A3 (fr) * 2006-12-21 2012-08-29 Paratek Pharmaceuticals, Inc. Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
AU2008246119A1 (en) * 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
JP5496202B2 (ja) 2008-08-08 2014-05-21 テトラフェース ファーマシューティカルズ，インコーポレイテッド Ｃ７−フルオロ置換テトラサイクリン化合物
WO2010126607A2 (fr) 2009-04-30 2010-11-04 President And Fellows Of Harvard College Synthèse de tétracyclines et intermédiaires de celles-ci
PL2427425T3 (pl) 2009-05-08 2017-08-31 Tetraphase Pharmaceuticals, Inc. Związki tetracyklinowe
ES2654987T3 (es) 2009-08-28 2018-02-15 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina
CN101967108B (zh) * 2010-09-13 2013-06-19 苏春华 一种美他环素的衍生物
WO2013013505A1 (fr) 2011-07-26 2013-01-31 山东亨利医药科技有限责任公司 Composé tétracycline substitué par 9-aminométhyle
DK2890673T3 (en) 2012-08-31 2019-03-18 Tetraphase Pharmaceuticals Inc tetracycline
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
KR102660864B1 (ko) 2016-10-19 2024-04-25 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
CN115380022A (zh) * 2018-04-06 2022-11-22 帕拉特克药品公司 萨瑞环素盐酸盐的制造方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
WO1999030720A1 (fr) * 1997-12-19 1999-06-24 New York University Inhibition de la cyclooxygenase-2 et du facteur de necrose des tumeurs alpha
WO2000064479A1 (fr) * 1999-04-27 2000-11-02 Antibody Systems, Inc. Compositions contenant des tetracyclines et servant a traiter des infections et d'autres maladies virales hemorragiques
WO2002000208A2 (fr) * 2000-06-29 2002-01-03 Jomaa Pharmaka Gmbh Preparations de derives d'acide 3-n-formylhydroxylaminopropylphosphonique ou de derives d'acide 3-n-acetylhydroxylaminopropylphosphonique combines avec des principes actifs pharmaceutiques speciaux
WO2002004406A2 (fr) * 2000-07-07 2002-01-17 Trustees Of Tufts College Composes de monocycline 9-substitues
WO2002004407A2 (fr) * 2000-07-07 2002-01-17 Trustees Of Tufts College Composes de tetracycline substitues en 7
WO2002072022A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues, en tant qu'agents antifongiques
WO2002072532A1 (fr) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues en position 7,9
WO2002085303A2 (fr) * 2001-04-24 2002-10-31 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues destines au traitement de la malaria
WO2003005971A2 (fr) * 2001-07-13 2003-01-23 Paratek Pharmaceuticals, Inc. Composes de tetracycline a activites therapeutiques cibles
WO2003079984A2 (fr) * 2002-03-21 2003-10-02 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (fr) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
YU40295B (en) 1977-04-07 1985-12-31 Pliva Pharm & Chem Works Process for preparing n2-tert.butyl-11a-halo-6-demethyl-6-deoxy-6-methylene tetracycline
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
YU41093B (en) 1978-04-12 1986-12-31 Pliva Pharm & Chem Works Process for preparing 6-deoxy-5hydroxy-tetracycline
SG47520A1 (en) * 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
EP0599397B1 (fr) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tétracyclines comprenant les tétracyclines modifiées chimiquement afin d'être non-antimicrobiennes inhibent la réticulation excessive du collagène lors du diabète
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5834450A (en) 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5919395A (en) 1997-10-30 1999-07-06 Shell Oil Company Polyol combination
JP2002501026A (ja) * 1998-01-23 2002-01-15 トルスティーズ オブ トゥフツ カレッジ 薬学的に活性の化合物及びその利用法
WO2000028983A1 (fr) * 1998-11-18 2000-05-25 Collagenex Pharmaceuticals, Inc. Nouveaux derives de 4-dedimethy laminotetra cycline
US6326023B1 (en) * 2000-03-28 2001-12-04 Council Of Scientific & Industrial Research Synergistic anti-malarial formulation
WO2002072031A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
EP2311451A1 (fr) * 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Composés de tétracycline à substitution amino-méthyle
EA201001081A1 (ru) * 2003-07-09 2011-02-28 Пэрэтек Фамэсьютикэлс, Инк. Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
JP5706185B2 (ja) 2011-02-22 2015-04-22 富士レビオ株式会社 測定装置及び測定方法
US9713502B2 (en) 2014-03-09 2017-07-25 Gyrus Acmi, Inc. Narrow band imaging with surgical loupes

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
WO1999030720A1 (fr) * 1997-12-19 1999-06-24 New York University Inhibition de la cyclooxygenase-2 et du facteur de necrose des tumeurs alpha
WO2000064479A1 (fr) * 1999-04-27 2000-11-02 Antibody Systems, Inc. Compositions contenant des tetracyclines et servant a traiter des infections et d'autres maladies virales hemorragiques
WO2002000208A2 (fr) * 2000-06-29 2002-01-03 Jomaa Pharmaka Gmbh Preparations de derives d'acide 3-n-formylhydroxylaminopropylphosphonique ou de derives d'acide 3-n-acetylhydroxylaminopropylphosphonique combines avec des principes actifs pharmaceutiques speciaux
WO2002004406A2 (fr) * 2000-07-07 2002-01-17 Trustees Of Tufts College Composes de monocycline 9-substitues
WO2002004407A2 (fr) * 2000-07-07 2002-01-17 Trustees Of Tufts College Composes de tetracycline substitues en 7
WO2002072532A1 (fr) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues en position 7,9
WO2002072022A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues, en tant qu'agents antifongiques
WO2002085303A2 (fr) * 2001-04-24 2002-10-31 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues destines au traitement de la malaria
WO2003005971A2 (fr) * 2001-07-13 2003-01-23 Paratek Pharmaceuticals, Inc. Composes de tetracycline a activites therapeutiques cibles
WO2003079984A2 (fr) * 2002-03-21 2003-10-02 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUNNANG D ET AL: "QUININE-TETRACYCLINE FOR MULTIDRUG RESISTANT FALCIPARUM MALARIA" SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, PROJECT OD SEAMEO, BANGKOK, vol. 27, no. 1, 1 March 1996 (1996-03-01), pages 15-18, XP009060760 ISSN: 0125-1562 *
DRAPER M P ET AL: "NOVEL TETRACYCLINE DERIVATIVES AS ANTIMALARIAL DRUGS" PROGRAM AND ABSTRACTS OF THE INTERSCIENCE CONFERENCE ONANTIMICROBIAL AGENTS AND CHEMOTHERAPY, PY, WASHINGTON, DC, vol. 41, 17 December 2001 (2001-12-17), page 496, XP001208128 ISSN: 0733-6373 *
See also references of WO2004038001A2 *
TOAMA M A: "IN VITRO SYNERGISM BETWEEN TETRACYCLINES AND ANTIMALARIALS" CHEMOTHERAPY, S. KARGER, BASEL, CH, vol. 26, no. 3, 1 January 1980 (1980-01-01), pages 191-195, XP009060770 ISSN: 0009-3157 *

Also Published As

Publication number Publication date
WO2004038001A3 (fr) 2004-11-11
AU2003287218A1 (en) 2004-05-13
EP2277504A1 (fr) 2011-01-26
IL209319A0 (en) 2011-01-31
AU2003287218B2 (en) 2009-12-17
CA2502464A1 (fr) 2004-05-06
AU2003287218C1 (en) 2010-07-15
WO2004038001A2 (fr) 2004-05-06
EP1556007A4 (fr) 2008-12-17
AU2010200971A1 (en) 2010-04-01
JP2006503898A (ja) 2006-02-02
AU2010200973A1 (en) 2010-04-01
JP2011037890A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
EP1399414B1 (fr) Composes de tetracycline substitues destines au traitement de la malaria
US8088820B2 (en) Substituted tetracycline compounds for the treatment of malaria
AU2002254714A1 (en) Substituted tetracycline compounds for the treatment of malaria
AU2003287218C1 (en) Substituted tetracycline compounds for the treatment of malaria
CA2415718C (fr) Composes de tetracycline substitues en 7
AU2005201623B2 (en) 9-substituted minocycline compounds
AU2001286388A1 (en) 9-substituted minocycline compounds
AU2001271642A1 (en) 7-substituted tetracycline compounds
US20130109617A1 (en) Substituted tetracycline compounds for treatment of bacillus anthracis infections
AU2009236631A1 (en) Substituted tetracycline compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050523

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NELSON, MARK, L.

Inventor name: DRAPER, MICHAEL

A4 Supplementary search report drawn up and despatched

Effective date: 20081119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 33/06 20060101ALI20081113BHEP

Ipc: A61K 31/65 20060101ALI20081113BHEP

Ipc: A61K 9/48 20060101ALI20081113BHEP

Ipc: A61K 9/02 20060101AFI20050429BHEP

17Q First examination report despatched

Effective date: 20090226

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101026